Efficacy and Safety of Aripiprazole Once-Monthly in the Maintenance Treatment of Bipolar I Disorder: A Double-Blind, Placebo-Controlled, 52-Week Randomized Withdrawal Study
Open accessAbstract
OBJECTIVE: To evaluate efficacy, safety, and tolerability of long-acting injectable antipsychotic aripiprazole once-monthly 400 mg (AOM 400) as maintenance treatment for bipolar I disorder (BP-I). METHODS: In a double-blind, placebo-controlled, 52-week randomized withdrawal study conducted from August 2012 to April 2016, patients with a DSM-IV-TR diagnosis of BP-I currently experiencing a manic episode were stabilized sequentially on oral aripiprazole and AOM 400 and then randomized to AOM 400 or placebo. The primary end point was time from randomization to recurrence of any mood episode. Other end points included proportion of patients with recurrence of any mood episode and recurrence by mood episode type. RESULTS: Of 266 randomized patients, 64 (48.1%) of 133 in the AOM 400 group and 38 (28.6%) of 133 in the placebo group completed the study. AOM 400 significantly delayed the time to recurrence of any mood episode compared with placebo (hazard ratio: 0.45; 95% CI, 0.30 to 0.68; P < .0001). Significantly fewer patients (P < .0001) experienced recurrence of any mood episode with AOM 400 (35/132; 26.5%) compared with placebo (68/133; 51.1%), with the effects observed predominantly on manic episodes (P < .0001). Patients were not depressed at study entry, and between-group differences in depressive episodes were not significant (P < .864). The treatment-emergent adverse events (incidence > 5%) that were reported at higher rates with AOM 400 than placebo were weight increase, akathisia, insomnia, and anxiety. CONCLUSIONS: AOM 400 delayed the time to and reduced the rate of recurrence of mood episodes and was generally safe and well tolerated. These findings support the use of AOM 400 for maintenance treatment of BP-I. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01567527.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Risperidone long-acting injectable monotherapy or adjunctive therapy once every 2 weeks or aripiprazole once-monthly injectable monotherapy has been shown to be effective in preventing relapse of mood episodes in patients with bipolar disorder.
“Risperidone long‐acting injectable monotherapy383 or adjunctive therapy (level 2)384 once every 2 weeks or aripiprazole once‐monthly injectable monotherapy (level 2)377 has been shown to be effective in preventing relapse of mood episodes in patients with BD.”
From Canadian Network for Mood and Anxiety Treatments ( <scp>CANMAT</scp> ) and International Society for Bipolar Disorders ( <scp>ISBD</scp> ) 2018 guidelines for the management of patients with bipolar disorder (2018) · cites this paper as [377]
Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
Experimental — accuracy not yet measuredAripiprazole oral or once monthly is effective in preventing any mood or manic episode, but it has not been shown to be effective in preventing depression.
“aripiprazole oral (level 2)375, 376 or once monthly (level 2)377 is also recommended as a first‐line monotherapy in view of its efficacy in preventing any mood or manic episode as well as its safety/tolerability profile, although it has not been shown to be effective in preventing depression.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
(1998) · The Journal of Clinical Psychiatry · Cited by 19,139 · see citing works
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962 · see citing works
A Rating Scale for Mania: Reliability, Validity and Sensitivity
Young, R. C., Biggs, J. T., Ziegler, V. E., & Meyer, D. A. (1978) · British Journal of Psychiatry · doi:10.1192/bjp.133.5.429 · Cited by 8,744 · see citing works
A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
Simpson, G. M., B., M., B., G., Angus, J. W. S., P., F. R. C., & M., D. P. (1970) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1970.tb02066.x · Cited by 3,265 · see citing works
A Rating Scale for Drug-Induced Akathisia
Barnes, T. R. E. (1989) · The British Journal of Psychiatry · doi:10.1192/bjp.154.5.672 · Cited by 2,179 · see citing works
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Beaulieu, S., Alda, M., O’Donovan, C., MacQUEEN, G. M., McIntyre, R. S., Sharma, V., et al. (2012) · Bipolar Disorders · doi:10.1111/bdi.12025 · Cited by 1,209 · see citing works
Spearing, M. K., Post, R. M., Leverich, G. S., Brandt, D., & Nolen, W. (1997) · Psychiatry Research · doi:10.1016/s0165-1781(97)00123-6 · Cited by 978 · see citing works
Aripiprazole Intramuscular Depot as Maintenance Treatment in Patients With Schizophrenia
Kane, J. M., Sanchez, R., Perry, P. P., Jin, N., Johnson, B. R., Forbes, R. A., McQuade, R. D., Carson, W. H., & Fleischhacker, W. W. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.11m07530 · Cited by 361 · see citing works
Self-citationCognitive dysfunction in bipolar disorder and schizophrenia: a systematic review of meta-analyses
Carvalho, A. F., Bortolato, B., Miskowiak, K. W., Vieta, E., & Köhler, C. A. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s76700 · Cited by 305 · see citing works
The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal
Brissos, S., Veguilla, M. R., Taylor, D., & Balanzá-Martinez, V. (2014) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125314540297 · Cited by 297 · see citing works
Sachs, G. S., Sanchez, R., Marcus, R. N., Stock, E. G., McQuade, R. D., Carson, W. H., Abou-Gharbia, N., Impellizzeri, C., Kaplita, S., Rollin, L., et al. (2006) · Journal of Psychopharmacology · doi:10.1177/0269881106059693 · Cited by 245 · see citing works
Self-citationTreatment adherence with antipsychotic medications in bipolar disorder
Sajatovic, M., Valenstein, M., Blow, F. C., Ganoczy, D., & Ignacio, R. V. (2006) · Bipolar Disorders · doi:10.1111/j.1399-5618.2006.00314.x · Cited by 242 · see citing works
López‐Jaramillo, C., Lopera-Vásquez, J. P., Gallo, A., Ospina‐Duque, J., Bell, V., Torrent, C., Martínez‐Arán, A., & Vieta, E. (2010) · Bipolar Disorders · doi:10.1111/j.1399-5618.2010.00835.x · Cited by 223 · see citing works
Risperidone Long-Acting Injectable Monotherapy in the Maintenance Treatment of Bipolar I Disorder
Quiroz, J. A., Yatham, L. N., Palumbo, J. M., Karcher, K., Kushner, S., & Kusumakar, V. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.01.015 · Cited by 200 · see citing works
Columbia-Suicide Severity Rating Scale
Posner, K. (2016) · PsycTESTS Dataset · doi:10.1037/t52667-000 · Cited by 199 · see citing works
Naber, D., Hansen, K., Forray, C., Baker, R. A., Sapin, C., Beillat, M., Peters-Strickland, T. S., Nylander, A., Hertel, P., Andersen, H. S., et al. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.07.007 · Cited by 156 · see citing works
Self-citationFlupenthixol decanoate in recurrent manic‐depressive illness: A COMPARISON WITH LITHIUM
Ahlfors, U. G., Baastrup, P. C., Dencker, S. J., Elgen, K., Lingjærde, O., Pedersen, V., Schou, M., & Aaskoven, O. (1981) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1981.tb00778.x · Cited by 155 · see citing works
Fleischhacker, W. W., Sanchez, R., Perry, P. P., Jin, N., Peters-Strickland, T. S., Johnson, B. R., Baker, R. A., Eramo, A., McQuade, R. D., Carson, W. H., et al. (2014) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.113.134213 · Cited by 153 · see citing works
Self-citationTreatment Nonadherence and Neurocognitive Impairment in Bipolar Disorder
Martínez‐Arán, A., Scott, J. L., Colom, F., Torrent, C., Tabarés‐Seisdedos, R., Daban, C., Leboyer, M., Henry, C., Goodwin, G. M., González-Pinto, A. M., et al. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04408 · Cited by 143 · see citing works
Robinson, D. G., Gallego, J. A., John, M., Petrides, G., Hassoun, Y., Zhang, J., Lopez, L. V., Braga, R. J., Sevy, S. M., Addington, J., et al. (2015) · Schizophrenia Bulletin · doi:10.1093/schbul/sbv125 · Cited by 112 · see citing works
Atypical antipsychotics in bipolar disorder: systematic review of randomised trials
Derry, S., & Moore, R. A. (2007) · BMC Psychiatry · doi:10.1186/1471-244x-7-40 · Cited by 92 · see citing works
Lage, M. J., & Hassan, M. (2009) · Annals of General Psychiatry · doi:10.1186/1744-859x-8-7 · Cited by 72 · see citing works
Kishi, T., Oya, K., & Iwata, N. (2016) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw038 · Cited by 71 · see citing works
Ishigooka, J., Nakamura, J., 藤井, 康., et al. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.12.013 · Cited by 70 · see citing works
Zimmerman, M. A., Galione, J. N., Chelminski, I., Young, D., Dalrymple, K. L., & Ruggero, C. J. (2010) · Bipolar Disorders · doi:10.1111/j.1399-5618.2010.00869.x · Cited by 67 · see citing works
Long-Acting Injectable Antipsychotics for the Maintenance Treatment of Bipolar Disorder
Gigante, A. D., Lafer, B., & Yatham, L. N. (2012) · CNS Drugs · doi:10.2165/11631310-000000000-00000 · Cited by 58 · see citing works
Correlates of Medication Adherence Among Patients With Bipolar Disorder
Bates, J. A., Whitehead, R. E., Bolge, S. C., & Kim, E. (2010) · The Primary Care Companion to The Journal of Clinical Psychiatry · doi:10.4088/pcc.09m00883yel · Cited by 49 · see citing works
Yatham, L. N., Fountoulakis, K. Ν., Rahman, Z. U., Ammerman, D., Fyans, P., Marler, S. V., Baker, R. A., & Carlson, B. X. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.11.042 · Cited by 45 · see citing works
Kanba, S., Kawasaki, H., Ishigooka, J., Sakamoto, K., Kinoshita, T., & Kuroki, T. (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2012.669047 · Cited by 31 · see citing works
Szmulewicz, A., Samamé, C., Caravotta, P., Martino, D. J., Igoa, A., Hidalgo-Mazzei, D., Colom, F., & Strejilevich, S. A. (2016) · International Journal of Bipolar Disorders · doi:10.1186/s40345-016-0047-3 · Cited by 28 · see citing works
Deltoid injections of risperidone long-acting injectable in patients with schizophrenia.
Quiroz, J. A., Rusch, S., Thyssen, A., Palumbo, J., & Kushner, S. F. (2011) · Europe PMC (PubMed Central) · Cited by 13 · see citing works
Flagged first, then by citations
Research works printed but not linked: 39
- American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder, second edition. APA web site. http://psychiatryonline.org/pb/assets/raw/ sitewide/practice_guidelines/guidelines/ bipolar.pdf. Accessed July 21, 2016.
- Grunze H, Vieta E, Goodwin GM, et al; WFSBP Task Force on Treatment Guidelines for Bipolar Disorders. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder. World J Biol Psychiatry. 2013;14(3):154-219.
- P u b M e d d o i : 1 0 . 3 1 0 9 / 1 5 6 2 2 9 7 5 . 2 0 1 3 . 7 7 0 5 5 · DOI
- Bortolato B, Miskowiak KW, Köhler CA, et al. Cognitive dysfunction in bipolar disorder and schizophrenia: a systematic review of meta- analyses. Neuropsychiatr Dis Treat. 2015;11:3111-3125.
- Martinez-Aran A, Scott J, Colom F, et al. Treatment nonadherence and neurocognitive impairment in bipolar disorder. J Clin Psychiatry. 2009;70(7):1017-1023.
- Zimmerman M, Galione JN, Chelminski I, et al. Sustained unemployment in psychiatric outpatients with bipolar disorder: frequency and association with demographic variables and comorbid disorders. Bipolar Disord. 2010;12(7):720-726.
- Baune BT, Malhi GS. A review on the impact of cognitive dysfunction on social, occupational, and general functional outcomes in bipolar disorder. Bipolar Disord. 2015;17(suppl 2):41-55. P u b M e d d o i : 1 0 . 1 1 1 1 / b d i . 1 2 3 4 1 · DOI
- López-Jaramillo C, Lopera-Vásquez J, Gallo A, et al. Effects of recurrence on the cognitive performance of patients with bipolar I disorder: implications for relapse prevention and treatment adherence. Bipolar Disord. 2010;12(5):557-567.
- Kemp DE. Managing the side effects associated with commonly used treatments for bipolar depression. J Affect Disord. 2014;169(suppl 1):S34-S44. P u b M e d d o i : 1 0 . 1 0 1 6 / S 0 1 6 5 -0 3 2 7 ( 1 4 ) 7 0 0 0 7 -2 · DOI
- Keck PE Jr, Calabrese JR, McIntyre RS, et al; Aripiprazole Study Group. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. J Clin Psychiatry. 2007;68(10):1480-1491.
- P u b M e d d o i : 1 0 . 4 0 8 8 / J C P . v 6 8 n 1 0 0 3 · DOI · Paper page
- Keck PE Jr, Calabrese JR, McQuade RD, et al; Aripiprazole Study Group. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry. 2006;67(4):626-637.
- P u b M e d d o i : 1 0 . 4 0 8 8 / J C P . v 6 7 n 0 4 1 4 · DOI · Paper page
- Yatham LN, Fountoulakis KN, Rahman Z, et al. Efficacy of aripiprazole versus placebo as adjuncts to lithium or valproate in relapse prevention of manic or mixed episodes in bipolar I patients stratified by index manic or mixed episode. J Affect Disord. 2013;147(1-3):365-372.
- Perlis RH, Ostacher MJ, Miklowitz DJ, et al. Clinical features associated with poor pharmacologic adherence in bipolar disorder: results from the STEP-BD study. J Clin Psychiatry. 2010;71(3):296-303.
- P u b M e d d o i : 1 0 . 4 0 8 8 / J C P . 0 9 m 0 5 5 1 4 y e l · DOI
- Sajatovic M, Valenstein M, Blow FC, et al. Treatment adherence with antipsychotic medications in bipolar disorder. Bipolar Disord. 2006;8(3):232-241.
- Velligan DI, Weiden PJ, Sajatovic M, et al; Expert Consensus Panel on Adherence Problems in Serious and Persistent Mental Illness. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry. 2009;70(suppl 4):1-46, quiz 47-48. P u b M e d d o i : 1 0 . 4 0 8 8 / J C P . 7 0 9 0 s u 1 c j · DOI
- McEvoy JP. Risks versus benefits of different types of long-acting injectable antipsychotics. J Clin Psychiatry. 2006;67(suppl 5):15-18. P u b M e d 23. Gigante AD, Lafer B, Yatham LN. Long-acting injectable antipsychotics for the maintenance treatment of bipolar disorder. CNS Drugs. 2012;26(5):403-420.
- Quiroz JA, Yatham LN, Palumbo JM, et al. Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder. Biol Psychiatry. 2010;68(2):156-162.
- Kane JM, Sanchez R, Perry PP, et al. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2012;73(5):617-624.
- Fleischhacker WW, Sanchez R, Perry PP, et al. Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study. Br J Psychiatry. 2014;205(2):135-144.
- Ishigooka J, Nakamura J, Fujii Y, et al; ALPHA Study Group. Efficacy and safety of aripiprazole once-monthly in Asian patients with schizophrenia: a multicenter, randomized, double-blind, non-inferiority study versus oral aripiprazole. Schizophr Res. 2015;161(2-3):421-428.
- International Conference on Harmonisation. E6: Good Clinical Practice: consolidated guideline. www.ich.org. Accessed July 26, 2016.
- Young RC, Biggs JT, Ziegler VE, et al. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429-435.
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000.
- Kim JH, Jung HY, Kang UG, et al. Metric characteristics of the Drug-Induced See supplementary material for this article at . Extrapyramidal Symptoms Scale (DIEPSS): a practical combined rating scale for drug- induced movement disorders. Mov Disord. 2002;17(6):1354-1359.
- P u b M e d d o i : 1 0 . 1 0 0 2 / m d s . 1 0 2 5 · DOI
- Guy W. Abnormal Involuntary Movement Scale (AIMS). In: ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976:534-537.
- Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672-676.
- P u b M e d d o i : 1 0 . 1 5 1 7 / 1 4 7 4 0 3 3 8 . 2 0 1 4 . 9 0 6 5 7 9 · DOI
- Calabrese JR, Vieta E, El-Mallakh R, et al. Mood state at study entry as predictor of the polarity of relapse in bipolar disorder. Biol Psychiatry. 2004;56(12):957-963.
- P u b M e d d o i : 1 0 . 1 0 1 6 / j . b i o p s y c h . 2 0 0 4 . 0 9 . 0 2 2 · DOI
- Ahlfors UG, Baastrup PC, Dencker SJ, et al. Flupenthixol decanoate in recurrent manic- depressive illness: a comparison with lithium. Acta Psychiatr Scand. 1981;64(3):226-237.
- White E, Cheung P, Silverstone T. Depot antipsychotics in bipolar affective disorder. Int Clin Psychopharmacol. 1993;8(2):119-122. P u b M e d d o i : 1 0 . 1 0 9 7 / 0 0 0 0 4 8 5 0 -1 9 9 3 0 0 8 2 0 -0 0 0 0 7 · DOI
- Robinson DG, Gallego JA, John M, et al. A randomized comparison of aripiprazole and risperidone for the acute treatment of first- episode schizophrenia and related disorders: 3-month outcomes. Schizophr Bull. 2015;41(6):1227-1236.
- Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429-435.
- Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389.
- Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W. Modification of the Clinical Global Impressions (CGI) scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res. 1997;73(3):159-171.
Cited by
Sorted by citations
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852 · see citing works
Self-citationGrunze, H., Vieta, E., Goodwin, G. M., Bowden, C., Licht, R. W., Azorin, J.-M., Yatham, L., Mosolov, S., Möller, H.-J., Kasper, S., et al. (2018) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2017.1384850 · Cited by 187 · see citing works
Kishi, T., Ikuta, T., Matsuda, Y., Sakuma, K., Okuya, M., Mishima, K., & Iwata, N. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-00946-6 · Cited by 169 · see citing works
Reversibility of Antipsychotic-Induced Weight Gain: A Systematic Review and Meta-Analysis
Speyer, H., Westergaard, C., Albert, N., Karlsen, M., Stürup, A. E., Nordentoft, M., & Krogh, J. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.577919 · Cited by 44 · see citing works
- Authors
- Calabrese, J. R., Sanchez, R., Jin, N., Amatniek, J., Cox, K., Johnson, B., Perry, P., Hertel, P., Such, P., Salzman, P. M., McQuade, R. D., Nyilas, M., & Carson, W. H.
- Affiliations
- University Hospitals Cleveland Medical Center (US)
- Otsuka (United States) (US)
- Lundbeck (Denmark) (DK)
- Corresponding author
- Calabrese, Joseph R.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2017-03-29
- Volume
- 78
- Issue
- 3
- Pages
- 324-331
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2581041194
- Cited by
- 135
- References
- 31
- Citations by year
- 2026: 9 · 2025: 8 · 2024: 13 · 2023: 6 · 2022: 10 · 2021: 35 · 2020: 11 · 2019: 15 · 2018: 24 · 2017: 4
- FWCI
- 12.11
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Abbott Laboratories
- Dainippon Sumitomo Pharma
- National Institute of Mental Health
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
- Keywords
- aripiprazole once-monthly, long-acting injectable antipsychotics, bipolar I disorder, maintenance therapy, mood episode recurrence, manic episodes, treatment-emergent adverse events, akathisia, weight gain, insomnia, tolerability
- MeSH terms
- Aripiprazole, Administration, Oral, Adult, Affect, Bipolar Disorder, Delayed-Action Preparations, Double-Blind Method, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Injections, Intramuscular, Male, Middle Aged, Recurrence, Substance Withdrawal Syndrome, Treatment Outcome, Kaplan-Meier Estimate, Drug Substitution
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
